Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Metamucil launches digital series promoting fibermaxxing trend for better health

Market News
09 Jun 2026
Not Specified
View Source
Bullish
pluang ai news

Metamucil has introduced "Metamucil Mic Grab," a new digital content series hosted by registered dietitian Amy Shapiro, featuring 90s icons Lance Bass and Danielle Fishel. The series aims to educate viewers on the fibermaxxing trend, which encourages prioritizing daily fiber intake to improve overall health. With nearly 90% of Americans not meeting fiber recommendations, the campaign highlights the benefits of psyllium fiber found in Metamucil, which supports digestion, heart health, blood sugar control, and appetite management. The initiative encourages consistent fiber consumption through diet and supplements to build sustainable wellness habits.

More News (GSK)

GSK buys cancer drug developer Nuvalent for $10.6B to boost lung cancer portfolio.

GSK buys cancer drug developer Nuvalent for $10.6B to boost lung cancer portfolio.

GSK has agreed to acquire Boston-based biotech firm Nuvalent for $10.6 billion in cash, paying $124 per share, a 40% premium over the last closing price. This marks GSK's largest acquisition in over a decade and aims to strengthen its lung cancer dru...

Company Fundamentals
Bullish
13 hours ago
FTSE 100 dips as GSK's £8bn US oncology deal raises investor concerns amid mixed global market moves

FTSE 100 dips as GSK's £8bn US oncology deal raises investor concerns amid mixed global market moves

The FTSE 100 fell slightly, led by a 3.5% drop in GSK shares following its £8 billion acquisition of US biotech firm Nuvalent, a deal larger than investors expected. While the acquisition aims to boost GSK's oncology pipeline and revenue from 2027, s...

Market News
Neutral
16 hours ago
Cancer drug developer Nuvalent jumps 39% after GSK agrees to buy it for $10.6 billion

Cancer drug developer Nuvalent jumps 39% after GSK agrees to buy it for $10.6 billion

British pharmaceutical company GSK announced it will acquire cancer drug developer Nuvalent for $10.6 billion. This deal caused Nuvalent's stock to surge 39% as investors reacted positively to the acquisition. The move highlights GSK's strategic inve...

Company Fundamentals
Bullish
18 hours ago
GSK buys biotech Nuvalent for $10.6B to boost its cancer drug portfolio.

GSK buys biotech Nuvalent for $10.6B to boost its cancer drug portfolio.

GSK has agreed to acquire U.S. biotech company Nuvalent for $10.6 billion, marking its largest purchase in eight years. This move aims to strengthen GSK's cancer drug offerings, which it had previously reduced. The deal follows GSK's 2018 acquisition...

Company Fundamentals
Bullish
20 hours ago
GSK to buy Nuvalent for $10.6B, boosting lung cancer drug pipeline and sales growth from 2027

GSK to buy Nuvalent for $10.6B, boosting lung cancer drug pipeline and sales growth from 2027

GSK has agreed to acquire US biotech firm Nuvalent for $10.6 billion (£8 billion) to enhance its oncology portfolio with advanced lung cancer treatments and other assets. The deal includes late-stage drugs zidesamtinib and neladalkib, both under FDA ...

Company Fundamentals
Bullish
21 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App